FDA Q1/Q2 Sameness Received for Fourth Product
- Troy Chavis
- Dec 1, 2018
- 1 min read
ChoroPharma, LLC has received FDA's response confirming Q1/Q2 sameness for our fourth ophthalmic suspension medication. Quality by design and registration batches are planned to begin Q1 2019.
Comments